Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa ...

DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...

Denali Therapeutics and Royalty Pharma entered a $275 million royalty funding agreement based on future sales of tividenofusp alfa.

Three years after the first ruling, the medical aid’s reconsideration bid thrusts the ongoing treatment dispute before the ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Now Ollie is making history as the world’s first successful gene therapy patient for this cruel condition. Ten months after ...

Shares of US drug developer Denali Therapeutics closed up 5.8% at $20.11 yesterday, after it announced a $275 million ...

Denali Therapeutics ( ($DNLI) ) has issued an update. On December 4, 2025, Denali Therapeutics entered into a $275 million synthetic royalty ...

Investing.com -- Denali Therapeutics Inc (NASDAQ:DNLI) stock rose 5.7% on Thursday after the company announced a $275 million synthetic royalty funding agreement with Royalty Pharma plc (NASDAQ:RPRX) ...

Denali Therapeutics ( ($DNLI) ) just unveiled an announcement. On December 4, 2025, Denali Therapeutics held its Investor Day, updating ...